Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaA Phase 2 Randomized Clinical Trial

Web

Oct. 28, 2019

Another disappointing clinical trial outcome, with the immunotherapy combo durvalumab plus tremelimumab (aPDL1 + aCTLA4) failing to produce a benefit in advanced disease (ORR 3% for combination). https://jamanetwork.com/journals/jamaoncology/article-abstract/2738420